title: Long-term outcomes of scleroderma renal crisis.
abstract: BACKGROUND
  Although scleroderma renal crisis, a complication of systemic sclerosis, can be treated with angiotensin-converting enzyme (ACE) inhibitors, its long-term outcomes are not known.
  
  
  OBJECTIVE
  To determine outcomes, natural history, and risk factors in patients with systemic sclerosis and scleroderma renal crisis.
  
  
  METHODS
  Prospective observational cohort study.
  
  
  METHODS
  University program specializing in scleroderma.
  
  
  METHODS
  145 patients with scleroderma renal crisis who received ACE inhibitors and 662 patients with scleroderma who did not have renal crisis.
  
  
  METHODS
  Among patients with renal crisis, the four outcomes studied were no dialysis, temporary dialysis, permanent dialysis, and early death. Demographic, clinical, and laboratory data were compared to identify risk factors for specific outcomes. Follow-up was 5 to 10 years.
  
  
  RESULTS
  61% of patients with renal crisis had good outcomes (55 received no dialysis, and 34 received temporary dialysis); only 4 of these (4%) progressed to chronic renal failure and permanent dialysis. More than half of the patients who initially required dialysis could discontinue it 3 to 18 months later. Survival of patients in the good outcome group was similar to that of patients with diffuse scleroderma who did not have renal crisis. Some patients (39%) had bad outcomes (permanent dialysis or early death).
  
  
  CONCLUSIONS
  Renal crisis can be effectively managed when hypertension is aggressively controlled with ACE inhibitors. Patients should continue taking ACE inhibitors even after beginning dialysis in hopes of discontinuing dialysis.
authors.affiliation: Georgetown University, 3800 Reservoir Road NW, LL Gorman, Washington, DC 20007, USA. steenv@gunet.georgetown.edu
authors.forename: V D
authors.initials: VD
authors.lastname: Steen
authors.forename: T A
authors.initials: TA
authors.lastname: Medsger
mesh_terms: D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D003404:Creatinine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006977:Hypertension, Renal / Q000150:complications / Q000188:drug therapy* / Q000209:etiology*; D007676:Kidney Failure, Chronic / Q000628:therapy; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis; D011446:Prospective Studies; D006435:Renal Dialysis; D012307:Risk Factors; D012595:Scleroderma, Systemic / Q000150:complications*; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D003404:Creatinine